Search

Ion Beam Applications

Закрыт

10.54 -1.5

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

10.2

Макс.

10.8

Ключевые показатели

By Trading Economics

Доход

-10M

Продажи

206M

P/E

Средняя по отрасли

41.111

63.778

Дивидендная доходность

1.56

Рентабельность продаж

-4.99

Сотрудники

1,943

EBITDA

-372K

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

1.56%

2.39%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

342M

Предыдущая цена открытия

12.04

Предыдущая цена закрытия

10.54

Ion Beam Applications График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 сент. 2024 г., 06:28 UTC

Приобретения, слияния, поглощения

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.